Evaluating the efficacy of medical countermeasures against bacterial and viral agents.

Dr. Comer’s research focuses on developing and characterizing animal models of infectious disease. These models are then used to test the efficacy of medical countermeasures against the infectious agent. Currently we are focusing on characterizing models of filovirus infections and utilizing these models to test novel countermeasures against Ebola and Marburg viruses.

The group has extensive experience designing and directing Good Laboratory Practice (GLP; 21 CFR Part 58)-compliant studies to test the efficacy of medical countermeasures to a variety of select agents. Dr. Comer has served in the role of Study Director on several studies submitted to the FDA for licensure of products under the "Animal Rule". Most notably was the approval of two therapeutic compounds used in the treatment of inhalational anthrax. Dr. Comer’s current research is aimed to facilitate the FDA licensure of new vaccines and therapeutics against BSL-4 agents.

Search PubMed Database for Publications